Strong Clinical Data led to EU Approval: in late 2007, the European Medicines Agency (EMA) granted marketing authorization for Gleolan® for the visualization of malignant tissue during surgery for malignant glioma (WHO grade III and IV).
Costas G. Hadjipanayis, MD, PhD at Mount Sinai in New York is sponsoring a multicenter experiential Gleolan® clinical trial. The goal is to include up to 20 centers (100 patients) across the United States. NXDC is providing regulatory and logistical support to this exciting opportunity for patients in the U.S. to benefit from Gleolan® use prior to FDA approval. If you would like to learn more about this clinical trial click here.
To receive additional information about getting trained to use Gleolan® please fill out the form below: